EPAS1 and renal cell carcinoma: There are several HIF-2α inhibitors in clinical development and one approved for indications such as renal cell carcinoma (Belzutifan, Merck).28 Such inhibitors can block the compensatory effects that partially increase tissue oxygenation in states of chronic hypoxia.